RANTES (CCL5) in Patients With Geographic Atrophy Age-Related Macular Degeneration
Translational Vision Science & Technology · 12.01.2023 · 12 (1) · 19
DOI: 10.1167/tvst.12.1.19 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Vision Science & Technology, erschienen am 12.01.2023. Verfasst von Cheryl N Fonteh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, USA. Hauptthemen laut MEDLINE: Geographic Atrophy, Macular Degeneration. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, NEI NIH HHS.
Abstract (Originalsprache)
Purpose
A previous study from our research group showed significantly lower levels of RANTES (Regulated upon Activation, Normal T Cell Expressed and Secreted) in patients with intermediate age-related macular degeneration (AMD) compared to control patients with no AMD. The primary aim of this study was to assess levels of RANTES in a cohort of patients with a more advanced form of the disease, geographic atrophy (GA), in comparison with controls.
Methods
The study was conducted on a cohort of patients with GA recruited into a Colorado AMD registry. Cases and controls were defined with multimodal imaging. Plasma levels of the chemokine RANTES were measured using a multiplex assay. A nonparametric (rank-based) regression model was fit to RANTES with a sex by AMD category interaction.
Results
The plasma levels of RANTES were significantly higher in the control group in comparison to the GA AMD group (median [interquartile range]): 10,204 [5799-19,554] pg/mL vs. 5435 [3420-9177] pg/mL, respectively, P < 0.01). When moderated by sex, there was no statistical difference between the male and female GA AMD or the male and female controls.
Conclusions
We found lower level of RANTES in patients with GA AMD compared with controls. This finding is consistent with the findings from our previous intermediate AMD study. However, in contrast to the results of our previous research, when moderated by sex there was no statistical difference between male and female GA patients. Translational Relevance: The biomarker RANTES is significantly lower in GA AMD patients compared to controls.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, USA.
- Colorado School of Public Health, University of Colorado School of Medicine, Aurora, CO, USA.
- Colorado Clinical and Translational Sciences Institute, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA.
Förderung
- NCATS NIH HHS
- NEI NIH HHS
Zitieren
APA
Fonteh, C. N., Palestine, A. G., Wagner, B. D., Patnaik, J. L., Mathias, M. T., Manoharan, N., Mandava, N., Baldermann, R., De Carlo, T., Lynch, A. M., & University of Colorado Retina Research Group (2023). RANTES (CCL5) in Patients With Geographic Atrophy Age-Related Macular Degeneration. Translational Vision Science & Technology, 12(1), 19. https://doi.org/10.1167/tvst.12.1.19
Vancouver
Fonteh CN, Palestine AG, Wagner BD, Patnaik JL, Mathias MT, Manoharan N, et al. RANTES (CCL5) in Patients With Geographic Atrophy Age-Related Macular Degeneration. Translational Vision Science & Technology. 2023;12(1):19. doi:10.1167/tvst.12.1.19
BibTeX
@article{Fonteh2023,
author = {Fonteh, Cheryl N and Palestine, Alan G and Wagner, Brandie D and Patnaik, Jennifer L and Mathias, Marc T and Manoharan, Niranjan and Mandava, Naresh and Baldermann, Rebecca and De Carlo, Talisa and Lynch, Anne M and University of Colorado Retina Research Group, University of Colorado Retina Research Group},
title = {RANTES (CCL5) in Patients With Geographic Atrophy Age-Related Macular Degeneration},
journal = {Translational Vision Science & Technology},
year = {2023},
volume = {12},
number = {1},
pages = {19},
doi = {10.1167/tvst.12.1.19}
}
EUVIMED